Clinical trial
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With…
NCT00435812 · Dynavax Technologies Corporation, Industry · Completed
Key facts
| NCT number | NCT00435812 |
|---|---|
| Title | Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine |
| Official title | A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B® |
| Lead sponsor | Dynavax Technologies Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | HEPLISAV and/or Placebo, Engerix-B |
| Enrollment | 2,428 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Feb 15, 2007 |
| Last update posted | Mar 20, 2019 |
| Countries | Canada, Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: